194 related articles for article (PubMed ID: 32232138)
1. Glycoengineering of Natural Killer Cells with CD22 Ligands for Enhanced Anticancer Immunotherapy.
Wang X; Lang S; Tian Y; Zhang J; Yan X; Fang Z; Weng J; Lu N; Wu X; Li T; Cao H; Li Z; Huang X
ACS Cent Sci; 2020 Mar; 6(3):382-389. PubMed ID: 32232138
[TBL] [Abstract][Full Text] [Related]
2. Glycoengineering of NK Cells with Glycan Ligands of CD22 and Selectins for B-Cell Lymphoma Therapy.
Hong S; Yu C; Wang P; Shi Y; Cao W; Cheng B; Chapla DG; Ma Y; Li J; Rodrigues E; Narimatsu Y; Yates JR; Chen X; Clausen H; Moremen KW; Macauley MS; Paulson JC; Wu P
Angew Chem Int Ed Engl; 2021 Feb; 60(7):3603-3610. PubMed ID: 33314603
[TBL] [Abstract][Full Text] [Related]
3. Nanobody-Engineered Natural Killer Cell Conjugates for Solid Tumor Adoptive Immunotherapy.
Gong L; Li Y; Cui K; Chen Y; Hong H; Li J; Li D; Yin Y; Wu Z; Huang Z
Small; 2021 Nov; 17(45):e2103463. PubMed ID: 34761524
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells.
Tian X; Zhang R; Qin H; Shi X; Qi W; Jiang D; Zhu T; Sun A
Cent Eur J Immunol; 2023; 48(1):1-13. PubMed ID: 37206593
[TBL] [Abstract][Full Text] [Related]
5. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
Matosevic S
J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
[TBL] [Abstract][Full Text] [Related]
6. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
Hu W; Wang G; Huang D; Sui M; Xu Y
Front Immunol; 2019; 10():1205. PubMed ID: 31214177
[TBL] [Abstract][Full Text] [Related]
7. Click Chemistry-Mediated Polymannose Surface-Engineering of Natural Killer Cells for Immunotherapy of Triple-Negative Breast Cancer.
Niu X; Yang H; Guo J; Yao L; Wang Y; Yu W; Liu Z; Chen H
Adv Healthc Mater; 2024 Jun; ():e2400970. PubMed ID: 38838184
[TBL] [Abstract][Full Text] [Related]
8. Natural killer cells modified with a Gpc3 aptamer enhance adoptive immunotherapy for hepatocellular carcinoma.
Zheng Y; Lai Z; Wang B; Wei Z; Zeng Y; Zhuang Q; Liu X; Lin K
Discov Oncol; 2023 Sep; 14(1):164. PubMed ID: 37665421
[TBL] [Abstract][Full Text] [Related]
9. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
[TBL] [Abstract][Full Text] [Related]
10. Tailoring tumor-recognizable hyaluronic acid-lipid conjugates to enhance anticancer efficacies of surface-engineered natural killer cells.
Lee CE; Kim S; Park HW; Lee W; Jangid AK; Choi Y; Jeong WJ; Kim K
Nano Converg; 2023 Dec; 10(1):56. PubMed ID: 38097911
[TBL] [Abstract][Full Text] [Related]
11. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
Oelsner S; Waldmann A; Billmeier A; Röder J; Lindner A; Ullrich E; Marschalek R; Dotti G; Jung G; Große-Hovest L; Oberoi P; Bader P; Wels WS
Int J Cancer; 2019 Oct; 145(7):1935-1945. PubMed ID: 30860598
[TBL] [Abstract][Full Text] [Related]
12. Purinergic targeting enhances immunotherapy of CD73
Wang J; Lupo KB; Chambers AM; Matosevic S
J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy.
Yang HG; Kang MC; Kim TY; Hwang I; Jin HT; Sung YC; Eom KS; Kim SW
J Immunother Cancer; 2019 May; 7(1):138. PubMed ID: 31126350
[TBL] [Abstract][Full Text] [Related]
14. Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective.
Cifaldi L; Locatelli F; Marasco E; Moretta L; Pistoia V
Trends Mol Med; 2017 Dec; 23(12):1156-1175. PubMed ID: 29133133
[TBL] [Abstract][Full Text] [Related]
15. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
[TBL] [Abstract][Full Text] [Related]
16. Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice.
Kozlowska AK; Kaur K; Topchyan P; Jewett A
Cancer Immunol Immunother; 2016 Jul; 65(7):835-45. PubMed ID: 27034236
[TBL] [Abstract][Full Text] [Related]
17. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
Michen S; Temme A
Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
[TBL] [Abstract][Full Text] [Related]
18. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
[TBL] [Abstract][Full Text] [Related]
19. Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.
Xiao L; Cen D; Gan H; Sun Y; Huang N; Xiong H; Jin Q; Su L; Liu X; Wang K; Yan G; Dong T; Wu S; Zhou P; Zhang J; Liang W; Ren J; Teng Y; Chen C; Xu XH
Mol Ther; 2019 Jun; 27(6):1114-1125. PubMed ID: 30962163
[TBL] [Abstract][Full Text] [Related]
20. Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivo.
Pegram HJ; Jackson JT; Smyth MJ; Kershaw MH; Darcy PK
J Immunol; 2008 Sep; 181(5):3449-55. PubMed ID: 18714017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
